# Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AAREYDRUGS · Pivot · prices to 22 Oct 2026

Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) closed at ₹111.75 on 22 Oct 2026, down 0.84% on the day. With a market capitalisation of ₹317 Cr, it ranks 2018th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 80.4× trailing earnings, against a return on equity of 2.9% in FY25. Over the past year the share price has risen 31.2%. Its 52-week range is ₹50.31 (30 Mar 2026) to ₹114.80 (19 Oct 2026); the last close is 2.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹189 Cr (+75.3% year on year) and net profit ₹2 Cr (+231.9%), on a standalone basis. Promoters held 37.71% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹111.75 |
| Market cap | ₹317 Cr |
| P/E (trailing) | 80.4 |
| ROE | 2.9% (FY25) |
| ROCE | 7.6% (FY25) |
| Debt to equity | 0.25 |
| 52-week high | ₹114.80 (19 Oct 2026) |
| 52-week low | ₹50.31 (30 Mar 2026) |
| 1-year return | +31.2% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹189 Cr | +75.3% | ₹2 Cr | +231.9% | ₹0.55 |
| Q3 FY26 | ₹96 Cr | −27.9% | ₹1 Cr | −20.8% | ₹0.20 |
| Q2 FY26 | ₹84 Cr | −20.0% | ₹1 Cr | −36.3% | ₹0.36 |
| Q1 FY26 | ₹102 Cr | −19.5% | ₹1 Cr | +10.5% | ₹0.48 |
| Q4 FY25 | ₹108 Cr | −48.6% | ₹0 Cr | −78.1% | ₹0.02 |
| Q3 FY25 | ₹134 Cr | +74.9% | ₹1 Cr | −29.4% | ₹0.26 |
| Q2 FY25 | ₹105 Cr | +81.8% | ₹2 Cr | +105.1% | ₹0.57 |
| Q1 FY25 | ₹127 Cr | +149.0% | ₹1 Cr | +72.2% | ₹0.44 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹474 Cr | ₹4 Cr |
| FY24 | ₹396 Cr | ₹5 Cr |
| FY23 | ₹419 Cr | ₹4 Cr |
| FY22 | ₹493 Cr | ₹7 Cr |
| FY21 | ₹348 Cr | ₹7 Cr |
| FY20 | ₹300 Cr | ₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 37.71%
- Foreign institutions: 4.80%
- Domestic institutions: 1.62%
- Non-institutions: 55.86%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹266.50 | ₹361 Cr | 36.9 | — |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |
| [Nureca](https://app.pivotnow.in/stock/NURECA) | ₹338.50 | ₹323 Cr | 159.7 | — |
| [Lyka Labs](https://app.pivotnow.in/stock/LYKALABS) | ₹82.64 | ₹299 Cr | — | — |
| [Bijoy Hans](https://app.pivotnow.in/stock/BIJHANS) | — | ₹292 Cr | — | — |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |

## Questions and answers

### What is the share price of Aarey Drugs & Pharmaceuticals today?

Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) last closed at ₹111.75 on 22 Oct 2026. Its 52-week high is ₹114.80 and its 52-week low is ₹50.31.

### What is the market cap of Aarey Drugs & Pharmaceuticals?

Aarey Drugs & Pharmaceuticals' market capitalisation is ₹317 Cr (₹317 Cr) at the 22 Oct 2026 close, ranking 2018th among the NSE companies Pivot tracks.

### What is the P/E ratio of Aarey Drugs & Pharmaceuticals?

Aarey Drugs & Pharmaceuticals trades at a trailing P/E of 80.4.

### What is the ROE and ROCE of Aarey Drugs & Pharmaceuticals?

Return on equity was 2.9% in FY25 and return on capital employed was 7.6% in FY25 (standalone figures).

### Is Aarey Drugs & Pharmaceuticals a debt-free company?

No. Aarey Drugs & Pharmaceuticals' debt-to-equity ratio was 0.25 in FY25, with total debt of ₹2 Cr.

### What were Aarey Drugs & Pharmaceuticals' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Aarey Drugs & Pharmaceuticals reported revenue of ₹189 Cr, +75.3% year on year, and net profit of ₹2 Cr, +231.9% year on year.

### How has Aarey Drugs & Pharmaceuticals stock performed over the last year?

Aarey Drugs & Pharmaceuticals' share price has risen 31.2% over the past year, +47.1% over three months and +11.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Aarey Drugs & Pharmaceuticals?

As of 30 Jun 2026: promoters 37.71%, foreign institutions 4.80%, domestic institutions 1.62%, non-institutions 55.86%.

### Who are Aarey Drugs & Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Aarey Drugs & Pharmaceuticals by market cap are Medicamen Biotech, Astal  Lab, Nureca, Lyka Labs, Bijoy Hans and Astonea Labs.

### Is Aarey Drugs & Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aarey Drugs & Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AAREYDRUGS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.